Clinical trials: Diabetes Mellitus II
Chronic Kidney Diseases, Type2Diabetes
Decision Support for Detection of Chronic Kidney Disease in Type II Diabetes Mellitus
While data from the National Health and Nutrition Examination Survey (NHANES) estimate that 36.9% of patients with diabetes have CKD, only approximately 10% of patients are aware of their kidney disease.
- Trial name
- CKD-DETECT (NCT05342545)
- Testing
- Alert-based computerized decision support
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Overweight or Obesity
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.
- Trial name
- NCT06973681
- Testing
- BGM0504
- Where
- China
- Volunteers
- 120 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Diabetes Mellitus Type I, Diabetes Mellitus Type II
A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use
This study seeks to evaluate a low-literacy strategy in a primary health care setting for promoting safe and effective prescription medication use among English and Spanish-speaking patients with diabetes.
- Trial name
- NCT01669473
- Testing
- EHR Based Strategy to promote Safe and Appropriate Drug Use
- Where
- 2 sites in United States
- Volunteers
- 541 people
- Sponsor
- Northwestern University
Type II Diabetes
Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes
The purpose of this study is to assess the safety and feasibility of the Fractyl Duodenal Remodeling System for the treatment of patients with poorly controlled Type 2 Diabetes.
- Trial name
- NCT01927562
- Testing
- Fractyl Duodenal Remodeling System
- Where
- Chile
- Volunteers
- 57 people
- Sponsor
- Fractyl Health Inc.
Chronic Glomerulonephritis, Diabetic Nephropathy
Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
The treatment period was 16 weeks, the initial dose, 5 mg, was unforcedly titrated to 10 mg, 20 mg and 40 mg after confirming tolerance at weeks 4, 8 and 12.
- Trial name
- NCT00914524
- Testing
- olmesartan medoxomil
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetes Mellitus, Type 1
Islet Transplant in Patients With Type I Diabetes
The primary objective of this study is to demonstrate the safety of allogenic islet transplantation in type 1 diabetic patients performed at the University of Virginia.
- Trial name
- NCT03698396
- Testing
- Allogenic Islet Cell Transplantation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kenneth Brayman, MD
T2DM
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.
- Trial name
- CT-L03 (NCT06571591)
- Testing
- CT-L03 Group 1, CT-L03 Group 2, Empagliflozin
- Where
- South Korea
- Volunteers
- 606 people
- Sponsor
- Celltrion
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment
Assessment of the effect of normal and impaired kidney function on the pharmacokinetics, pharmacodynamics and safety of BI 10773
- Trial name
- NCT01907113
- Testing
- BI 10773
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Diabetes
PEARL Program: Empowerment Program for Patients With Type 2 Diabetes (HK4)
Quality diabetes care requires informed-decisions of motivated care providers and diabetes patients. The investigators aim to use peer support and information technology to facilitate care providers to implement structured care…
- Trial name
- PEARL (NCT00950716)
- Testing
- Patient Peer Support and Empowerment, Usual Care
- Where
- China
- Volunteers
- 632 people
- Sponsor
- Chinese University of Hong Kong
Foot Ulcer, Diabetic
A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers
This is a Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of three different doses of topically applied telbermin in subjects ≥ 18 years old with diabetic foot ulcers.
- Trial name
- NCT00351767
- Testing
- telbermin
- Volunteers
- 170 people
- Sponsor
- Genentech, Inc.
Type II Diabetes
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378
A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-378
- Trial name
- NCT05741437
- Testing
- CKD-378, QD, PO Drug: D745, D150, QD, PO
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Obesity, Diabetes Mellitus, Type 2
Multicomponent Intervention on Lifestyle, Anthropometric Measurements, Glycemic Control and Quality of Life in Patients Obese People With Type II Diabetes
The main objective of this study will be to evaluate the effectiveness of a multicomponent intervention on nutritional recommendations and physical activity on glycemic control in obese patients with Type II Diabetes (DM2) in…
- Trial name
- Diabesity (NCT06222775)
- Testing
- Group session 1, Group session 2, Group session 3
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Castilla-La Mancha Health Service
it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either
Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients
Diabetes mellitus (DM) and its vascular complications are the one of the most prevalent diseases in the state of Qatar. It is a multifactorial disease associated with the development of retinopathy, nephropathy, neuropathy…
- Conditions
- it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either, Because the Body Does Not Produce Enough Insulin,, or Because Cells do Not Respond to the Insulin That
- Trial name
- NCT01226537
- Testing
- Taurine
- Volunteers
- 20 people
- Sponsor
- Hamad Medical Corporation
Peripheral Diabetic Neuropathy
Effects of Moderate Physical Activity on Early Symptoms of Peripheral Diabetic Neuropathy in Type-II Diabetes: A Randomized Clinical Trial
This study determines the effects of moderate physical activity on early symptoms of peripheral diabetic neuropathy in type-II diabetes. Most of the literature shows the impact of physical activity to manage/controlling diabetes.
- Trial name
- NCT05491850
- Testing
- Moderate Physical Activity for Peripheral Diabetic Neuropathy
- Where
- Pakistan
- Volunteers
- 17 people
- Sponsor
- Riphah International University
Diabetes Mellitus, Schizophrenia
Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II
The purpose of this study is to learn more about the relationship between serious mental illness and the detection and management of diabetes and pre-diabetic conditions.
- Conditions
- Diabetes Mellitus, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00377117
- Testing
- Management, Screening
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Gastroparesis
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.
- Trial name
- NCT00861809
- Testing
- GSK962040 25 mg, GSK962040 50 mg, GSK962040 1250 mg
- Where
- 2 sites in Belgium, Sweden
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of…
- Trial name
- NCT07112872
- Testing
- RO7795081, Semaglutide
- Where
- 46 sites in United States, Hungary and 2 more
- Volunteers
- 330 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
A Study In Patients With Type 2 Diabetes Mellitus
This study evaluates the effect of medicines for type 2 diabetes and lipids control. This study will require about 6 office visits for lab tests and examinations.
- Trial name
- NCT00256867
- Testing
- GSK523338
- Where
- 85 sites in United States, Australia and 4 more
- Volunteers
- 369 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.
The primary purpose of this study is to compare the effects of pioglitazone, once daily (QD), versus glimepiride on the amount of thickening of the carotid artery.
- Trial name
- CHICAGO (NCT00225264)
- Testing
- Pioglitazone, Glimepiride
- Where
- United States
- Volunteers
- 458 people
- Sponsor
- Takeda
Diabetic Nephropathy
Adiponectin and Insulin Resistance in Diabetic Nephropathy
Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB)…
- Trial name
- NCT00774904
- Testing
- Losartan
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xi'an Jiaotong University